Q1 EPS Estimate for Sanuwave Health Lowered by Analyst

Sanuwave Health Inc. (NASDAQ:SNWV) – Research analysts at Northland Securities decreased their Q1 2026 earnings estimates for Sanuwave Health in a note issued to investors on Friday, April 17th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.12). The consensus estimate for Sanuwave Health’s current full-year earnings is $0.40 per share. Northland Securities also issued estimates for Sanuwave Health’s FY2026 earnings at ($0.08) EPS.

Sanuwave Health (NASDAQ:SNWV) last announced its earnings results on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). The firm had revenue of $13.09 million during the quarter, compared to the consensus estimate of $13.23 million. Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.

Several other equities analysts also recently issued reports on SNWV. Zacks Research downgraded shares of Sanuwave Health from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Wall Street Zen downgraded shares of Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, March 27th. Finally, Roth Mkm restated a “buy” rating and set a $47.00 price objective (down from $53.00) on shares of Sanuwave Health in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Sanuwave Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Sanuwave Health Stock Performance

Shares of Sanuwave Health stock opened at $19.36 on Tuesday. The company has a market capitalization of $166.38 million, a PE ratio of -120.99 and a beta of 1.51. The company has a debt-to-equity ratio of 10.08, a quick ratio of 1.05 and a current ratio of 1.38. The company has a 50-day simple moving average of $21.05 and a two-hundred day simple moving average of $27.19. Sanuwave Health has a one year low of $16.27 and a one year high of $46.58.

Hedge Funds Weigh In On Sanuwave Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in Sanuwave Health in the 2nd quarter worth approximately $26,000. BNP Paribas Financial Markets acquired a new position in Sanuwave Health in the 2nd quarter worth approximately $46,000. Farther Finance Advisors LLC acquired a new position in Sanuwave Health in the 3rd quarter worth approximately $57,000. Russell Investments Group Ltd. acquired a new position in Sanuwave Health in the 3rd quarter worth approximately $67,000. Finally, State of Alaska Department of Revenue acquired a new position in Sanuwave Health in the 4th quarter worth approximately $96,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.